Renalytix Plc RENX

Renalytix PLC (AIM:RENX, OTC:RNLXY, FRA:2O9)) advanced to 6p, up 7%, alongside disclosures of a larger UBS holding and share purchases by chief executive James McCullough. The kidney diagnostics company reported UBS voting rights of 6.62%, up from 5.17% in the previous notification, in a...

Shares in Renalytix PLC (AIM:RENX, OTC:RNLXY, FRA:2O9) jumped 19% to 5p on Tuesday as trading resumed following a fundraise that pulled in £10.5 million for the AIM-listed diagnostics firm. The company had paused trading in its shares at the start of September while it lined up new...

In recent months, Renalytix PLC, Humanity Health Inc., and Quest Diagnostics have announced new collaborations and product launches, including a nationwide kidneyintelX.dkd testing program, a Humanity Biological Age wellness add-on on questhealth.com, and expanded AD-Detect blood-based Alzheimer’s tests accessible through Quest’s U.S. collection network. Together, these moves highlight Quest’s push to deepen its role in advanced kidney, brain health, and consumer-oriented wellness testing...

BOSTON, August 27, 2026--Carna Health, an AI-enabled digital health company revolutionizing Cardio-Kidney-Metabolic (CKM) care, today announced several strategic leadership appointments, including the addition of multidisciplinary healthcare and technology experts as strategic advisors. The appointments bring expertise across AI, business development, technology, and public health to support the company’s continued growth and global expansion, building on strategic partnerships with Siemens Heal

Renalytix PLC (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, today announced results published in the peer-reviewed medical journal Diabetes, Obesity and Metabolism from its most comprehensive real-world evidence (RWE) study to date for its FDA-approved kidneyintelX.dkd test.

Shares in Renalytix PLC (AIM:RENX, OTC:RNLXY, FRA:2O9) climbed 24% to 2.35p after the precision diagnostics company published two-year data showing its kidney disease test was linked to lasting improvements in patient health. The study of 2,470 patients with type 2 diabetes and early-stage...

Renalytix PLC (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, and Carna Health, an AI-enabled digital health company revolutionizing chronic disease prevention, both leaders in improving outcomes in chronic kidney disease (CKD), today announced a landmark partnership designed to transform how health systems identify, stratify, and manage chronic kidney disease and its interconnected cardiovascular-kidney-metabolic (CKM) complications.

Renalytix PLC (AIM:RENX, OTC:RNLXY, FRA:2O9) shares dropped 25% to 4.25p after the company posted first-half revenues of $1.6 million and flagged slower-than-expected progress in rolling out its kidney disease diagnostic test. The company, which develops the FDA-approved and...

Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision-medicine diagnostics company for kidney health and developer of kidneyintelX.dkd, the only FDA-approved and Medicare-reimbursed prognostic test for early-stage risk assessment in chronic kidney disease (CKD), announced the publication of pivotal new data in Diabetes Care, the top-ranked global diabetes journal of the American Diabetes Association.